Litcius/Paper detail

LBA2 Lorlatinib vs crizotinib in the first-line treatment of patients (pts) with advanced ALK-positive non-small cell lung cancer (NSCLC): Results of the phase III CROWN study

Benjamin Solomon, Todd M. Bauer, Filippo de Marinis, Enriqueta Felip, Yasushi Goto, G. Liu, Julien Mazières, Dongwook Kim, Tony Mok, Anna Polli, H. Thurm, Anna Maria Calella, Gerson Peltz, Alice T. Shaw

2020Annals of Oncology23 citationsDOI

Topics & Concepts

CrizotinibMedicineInternal medicineInterim analysisLung cancerClinical endpointALK inhibitorOncologyDiscontinuationAdverse effectProgression-free survivalRandomized controlled trialOverall survivalMalignant pleural effusionLung Cancer Treatments and MutationsLung Cancer Diagnosis and TreatmentLung Cancer Research Studies
LBA2 Lorlatinib vs crizotinib in the first-line treatment of patients (pts) with advanced ALK-positive non-small cell lung cancer (NSCLC): Results of the phase III CROWN study | Litcius